Dr. Changchun Deng, MD

Dr. Deng practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Deng's NPI, 1396866034, was assigned on April 2, 2007. Dr. Deng holds New York license 250367.

Dr. Deng's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Deng's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Deng is also affiliated with University Hospitals St. John Medical Center. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Deng to 3 more hospitals, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deng practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Deng's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Deng is licensed in New York.

CMS data shows 517 Medicare services from Dr. Deng across 8 procedure codes in 2024, for 134 Medicare patients. Medicare paid $42,487 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 134 Medicare patients who saw Dr. Deng in 2024. The largest group is 65 to 74, with 69 patients. 74% of them have high cholesterol, and 72% have high blood pressure. 8% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Deng's median patient age at 73, with 45% women.

In 2024, Dr. Deng wrote 681 Medicare Part D claims for 90 patients. 68% of them were for generic drugs. CMS names the drug for 569 of them, across 14 drugs with 11 or more claims each, at $2,696,488 in total drug cost. In 2023, CMS named 176 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Deng for performance year 2024, reported as part of a group. Dr. Deng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Deng as offering telehealth.

Dmand AI links Dr. Deng to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell and Leukemia, B-Cell. Open Payments lists research payments to Dr. Deng that name 1 trial.

CMS Open Payments shows 75 general payments to Dr. Deng from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 54% of the total. BeOne Medicines USA, Inc. paid the most, $9,343. It also lists 1 research payment totaling $1,346 in 2023, naming 1 clinical trial.